Data on 9,795 type 2 diabetes patients with at least moderate renal impairment revealed that those who took daily doses of fenofibrate for five years attained an 11% reduction in total cardiovascular events regardless of impairment severity, compared with those who took a placebo. The treatment also did not appear to increase drug-related safety concerns among diabetes patients with moderate renal impairment, compared with those with mild renal impairment, researchers reported in Diabetes Care.

Related Summaries